Zoeken
Algemene medische oncologie

Klinische studies borsttumoren

Op deze pagina

Planned

ARIADNE

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

DS1103-074

A Phase 1 randomized study with DS-1103a including dose optimization combined with T-DXd in HER2 Low / Ultra Low unresectable or metastatic Breast cancer. 

HERTHENA-Breast02 / U31402-287

Phase 1b/2 study : Multicenter, Open-label, Dose Escalation and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) in Combination with Trastuzumab Deruxtecan (T-DXd) in Participants with HER2-low, Unresectable or Metastatic Breast Cancer

  • Principal investigator : Dr. Françoise Derouane
  • Sponsor: Daiichi Sankyo
  • More information :
  • Indication:
  • Internal reference number : S72400

OPTImaL

Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumorinfiltrating

lymphocytes

  • Principal investigator : Dr. Yannick Van Herck
  • Sponsor: NKI Nederlands Kanker Instituut
  • More information : NCT06476119
  • Indication:  triple-negative breast cancer with high stromal tumorinfiltrating lymphocytes
  • Internal reference number : s71073

SNV4818-101 

A Phase 1 , Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Cmbination With Other Anticancer Agents in Participants With Advanced Solid Tumors 

Ongoing

ASCENT-05 (GS-US-595-6184)

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

AURORA BIG 14-01 / EORTC 1408

Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer

BEAMION BCGC-1  -  BI1479-0012

Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)

  • Principal investigator : Prof. Dr. Hans Wildiers
  • Sponsor: Boehringer Ingelheim
  • More information : NCT06324357
  • Indication: HER2+ metastatic + gastric/GEjunction/esophageal
  • Internal reference number : s68772

BrainStorm - IJB-BS-ODN-006

A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

BReNNA - WO46069

A randomized, open-label, multicenter, adaptive, phase II/III study of the blood-brain barrier penetrant RO7771950 versus tucatinib, both in combination with trastuzumab and capecitabine, in patients with pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases

DS3939-077

PHASE 1/2, OPEN-LABEL, MULTICENTER, FIRST-IN-HUMAN STUDY OF DS-3939a IN SUBJECTS WITH ADVANCED SOLID TUMORS

 

HERMIA - ABS011-1 

Evaluating the Diagnostic Performance of HER2 targeted PET/CT with ABS011 in metastatic Breast Cancer – HERMIA study

  • Principal investigator : Prof. Dr. Hans Wildiers
  • Sponsor : Abscint
  • More information :
  • Indication: 
  • Internal reference number : s69612

HERTHENA - U31402-277

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Open-label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced or Metastatic Solid Tumors

OPT-PEMBRO

OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab

PIKture-01   OKI-219-101 

PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants with Advanced Solid Tumors and in Combination with Endocrine Therapy or HER2-Targeted Therapy in Participants with Advanced Breast Cancer

ROSETTA (BNT327-05)

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC whose tumor PD-L1 status is considered negative

  • Principal investigator : Dr. Yannick Van Herck
  • Sponsor: BioNTech
  • More information : NCT07173751
  • Indication: untreated locally recurrent inoperable or metastatic TNBC
  • Internal reference number : s71189

Other

Clinical Studies Multidisciplinary Breast Center (MBC)

The multidisciplinary breast center (MBC) focuses on the diagnosis and treatment of all problems with your breasts, both benign breast conditions and breast cancer.

More information: overview of studies.

Laatste aanpassing: 24 juni 2026